Skip to Main Content
Contribute Try STAT+ Today

While pharmaceutical regulatory authorities in other countries are employing creative ways like video-based remote inspections to fulfill their obligations to the public, the U.S. Food and Drug Administration remains committed to conventional on-site inspections. By September 2020, the Covid-19 pandemic had precipitated a virtual pause in drug inspections: Roughly 85% of inspections had been curbed within U.S. borders and 99.5% outside the country.

Inspecting manufacturing facilities is a vital part of drug approval and production, and backlogs can cause huge delays, creating drug shortages in the global supply chain and threatening another global health crisis. Inspections are a key tool the FDA uses to ensure that drug producers adhere to manufacturing and record-keeping requirements, which ensures the safety of drugs on the market. Drug producers cannot legally operate without passing initial or recurring inspections.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.